International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006, 355: 1763-71. 10.1056/NEJMoa060476.
Article
Google Scholar
Mulshine JL, Sullivan D: Lung cancer screening. N Engl J Med. 2005, 352: 2714-20. 10.1056/NEJMcp042630.
Article
CAS
PubMed
Google Scholar
Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, Smith JP: Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999, 354: 99-105. 10.1016/S0140-6736(99)06093-6.
Article
CAS
PubMed
Google Scholar
Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982, 30: 403-408. 10.1002/ijc.2910300404.
Article
CAS
PubMed
Google Scholar
Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC: Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clinical Cancer Research. 1996, 2: 1767-1775.
CAS
PubMed
Google Scholar
Sangrajrang S, Sornprom A, Chernrungroj G, Soussi T: Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. Lung Cancer. 2003, 39: 297-301. 10.1016/S0169-5002(02)00509-3.
Article
PubMed
Google Scholar
Li Y, Brandt-Rauf PW, Carney WP, Tenney DY, Ford JD: Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking. Biomarkers. 1999, 4: 381-390. 10.1080/135475099230769.
Article
CAS
Google Scholar
Diesinger I, Bauer C, Brass N, Schaefers HJ, Comtesse N, Sybrecht G, Meese E: Towards a more complete recognition of immunoreactive antigens in squamous cell lung adenocarcinoma. Int J Cancer. 2002, 102: 372-8. 10.1002/ijc.10714.
Article
CAS
PubMed
Google Scholar
Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ: A survey of humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998, 187: 1349-54. 10.1084/jem.187.8.1349.
Article
CAS
PubMed
PubMed Central
Google Scholar
Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM: Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest. 1993, 92: 2419-2426. 10.1172/JCI116848.
Article
CAS
PubMed
PubMed Central
Google Scholar
Old LJ, Chen YT: New paths in human cancer serology. J Exp Med. 1998, 187: 1163-7. 10.1084/jem.187.8.1163.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tan EM: Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest. 2001, 108: 1411-1415.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dalman J, Furneaux HM, Cordon-Cardo C, Posner JB: The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Path. 1992, 141: 881-886.
Google Scholar
Darnell RB: Onconeural antigens and the paraneoplastic disorders: at the intersection of cancer, immunity and the brain. Proc Natl Acad Sci USA. 1996, 93: 4529-4536. 10.1073/pnas.93.10.4529.
Article
CAS
PubMed
PubMed Central
Google Scholar
Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High-titer HER-2/neu protein specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol. 1997, 15: 3363-7.
CAS
PubMed
Google Scholar
Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM: Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology. 1997, 25: 75-80. 10.1002/hep.510250114.
Article
CAS
PubMed
Google Scholar
Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY: Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999, 45: 162-7. 10.1002/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO;2-R.
Article
CAS
PubMed
Google Scholar
Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA: Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thoracic Oncology. 2006, 1: 513-519. 10.1097/01243894-200607000-00003.
Article
Google Scholar
Zhang JY, Chan EK, Peng XX, Lu M, Wang X, Mueller F, Tan EM: Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol. 2001, 100: 149-156. 10.1006/clim.2001.5048.
Article
CAS
PubMed
Google Scholar
Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM: An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA. 2001, 98: 9824-9829. 10.1073/pnas.171320598.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brichory F, Beer D, Le Naour F, Giordano T, Hanash S: Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001, 61: 7908-12.
CAS
PubMed
Google Scholar
Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Tureci O, Wiewrodt R, Barnes AC, Robertson JF: Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax. 2008, 63: 228-233. 10.1136/thx.2007.083592.
Article
CAS
PubMed
Google Scholar
Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EKL, Tan EM: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003, 12: 136-143.
CAS
PubMed
Google Scholar
Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, Chan EK, Tan EM: Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res. 2003, 9: 5120-6.
CAS
PubMed
Google Scholar
Shi FD, Zhang JY, Liu D, Rearden A, Elliot M, Nachtsheim D, Daniels T, Casiano CA, Heeb MJ, Chan EK, Tan E: Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate. 2005, 63: 252-258. 10.1002/pros.20181.
Article
CAS
PubMed
Google Scholar
Himoto T, Kuriyama S, Zhang JY, Chan EK, Kimura Y, Masaki T, Uchida N, Nishioka M, Tan EM: Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol. 2005, 27: 1079-1085.
CAS
PubMed
Google Scholar
Zhang JY, Chan EK, Peng XX, Tan EM: A novel protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med. 1999, 189: 1101-1110. 10.1084/jem.189.7.1101.
Article
CAS
PubMed
PubMed Central
Google Scholar
Soo Hoo L, Zhang JY, Chan EK: Cloning and characterization of a novel 90 kDa "companion" auto-antigen of p62 overexpressed in cancer. Oncogene. 2002, 21: 5006-15. 10.1038/sj.onc.1205625.
Article
PubMed
Google Scholar
Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG: Proteomic analysis of lung adenocarcinoma: Identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 2002, 8: 2298-2305.
CAS
PubMed
Google Scholar
Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, Kardia SL, Iannettoni MD, Yee J, Hogg PJ, Orringer MB, Hanash SM, Beer DG: Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA. 2003, 100: 13537-42. 10.1073/pnas.2233850100.
Article
CAS
PubMed
PubMed Central
Google Scholar
Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF: Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin A as potential molecular targets in non-small cell lung cancer. Cancer Res. 2003, 63: 1652-1656.
CAS
PubMed
Google Scholar
Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE, Fitzgerald MC, Bepler G, Patz EF: Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer. 2004, 46: 313-323. 10.1016/j.lungcan.2004.05.013.
Article
PubMed
Google Scholar
Gao WM, Kuick R, Orchekowski RP, Misek DE, Qiu J, Greenberg AK, Rom WN, Brenner DE, Omenn GS, Haab BB, Hanash SM: Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer. 2005, 5: 110-10.1186/1471-2407-5-110.
Article
PubMed
PubMed Central
Google Scholar
Sin DD, Man SFP, McWilliams A, Lam S: Progression of airway dysplasia and C-Reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med. 2006, 173: 535-9. 10.1164/rccm.200508-1305OC.
Article
CAS
PubMed
Google Scholar
Qiu J, Choi G, Lin L, Wang H, Pitteri S, Pereira-Faca S, Krasnoselsky A, Randolph T, Omenn G, Edelstein C, Barnett M, Thornquist M, Goodman G, Brenner D, Feng Z, Hanash S: Occurrence of autoantibodies to Annexin I, 14-3-3 Theta, and LAMR1 in prediagnostic lung cancer sera. J Clin Oncology. 2008, 26: 1-8. 10.1200/JCO.2007.14.5920.
Article
CAS
Google Scholar
Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ, Hirschowitz EA: Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev. 2003, 27: 285-90. 10.1016/S0361-090X(03)00097-7.
Article
CAS
PubMed
Google Scholar
Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA: Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med. 2005, 172: 1308-1314. 10.1164/rccm.200505-830OC.
Article
PubMed
PubMed Central
Google Scholar
Furukawa C, Daigo Y, Ishikawa N, Kato T, Ito T, Tsuchiya E, Sone S, Nakamura Y: Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res. 2005, 65: 7102-7110. 10.1158/0008-5472.CAN-04-1877.
Article
CAS
PubMed
Google Scholar
Chen G, Wang X, Yu J, Varambally S, Yu J, Thomas DG, Lin MY, Vishnu P, Wang Z, Wang R, Fielhauer J, Ghosh D, Giordano TJ, Giacherio D, Chang AC, Orringer MB, El-Hefnawy T, Bigbee WL, Beer DG, Chinnaiyan AM: Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res. 2007, 67: 3461-3467. 10.1158/0008-5472.CAN-06-4475.
Article
CAS
PubMed
Google Scholar
Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T: Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res. 2001, 21: 3085-92.
CAS
PubMed
Google Scholar
Nakata M, Saeki H, Takata I, Segawa Y, Mogami H, Mandai K, Eguchi K: Focal ground-glass opacity detected by low-dose helical CT. Chest. 2002, 121: 1464-7. 10.1378/chest.121.5.1464.
Article
PubMed
Google Scholar